Protective effect of captopril on ischemic myocardium

Area of Science:

• Cardiovascular Science
• Pharmacology
• Cell Biology

Background:

• Myocardial ischemia can lead to cellular damage through various mechanisms.
• Angiotensin-converting enzyme inhibitors (ACE-I) are known for their hemodynamic effects in cardiovascular disease.
• The specific protective mechanisms of ACE-I at the organelle level during ischemia require further elucidation.

Purpose of the Study:

• To investigate the protective effects of the ACE-I captopril on myocardial organelles during ischemia.
• To elucidate the mechanism of action of captopril in preventing ischemic damage at the cellular level.

Main Methods:

• A canine coronary ligation model was used to induce myocardial ischemia.
• Sarcoplasmic reticulum (SR) and mitochondrial fractions were isolated from ischemic and non-ischemic myocardial cells.
• Enzyme activities (Ca-ATPase, respiratory control ratio, DNP-stimulated ATPase) and sulfhydryl (SH) group content were measured.

Main Results:

• Captopril treatment did not significantly alter heart rate, cardiac output, or right ventricular systolic blood pressure compared to controls.
• Left ventricular systolic blood pressure decreased in both groups after ligation, with a more gradual decline in the captopril group.
• Ca-ATPase activity, respiratory control ratio, and DNP-stimulated ATPase activity were significantly higher in ischemic myocardium from captopril-treated hearts.
• SH group content in SR and mitochondria was elevated in the captopril-treated group.

Conclusions:

• ACE-I agents like captopril offer myocardial protection against ischemic damage through mechanisms beyond their hemodynamic effects.
• Captopril appears to protect cardiac organelles by preventing enzyme oxidation, preserving their function.
• The presence of sulfhydryl (SH) groups in ACE-I may be crucial for this protective effect against oxidative damage in myocardial ischemia.